search
Back to results

Stimulation of the Cervical Sympathetic Ganglion for Treatment of Asthma

Primary Purpose

Asthma

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Neurostimulation of stellate ganglion
Sponsored by
Jonathan Parsons
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. All patients aged 18-70 years of age suffering from mild-to-moderate asthma who have either:

    1. bronchial hyper-responsiveness to MCT
    2. bronchial hyper-responsiveness to EVH testing
  2. All patients with documented evidence of a positive MCT or EVH test within 36 months of Visit 1
  3. Are capable of reading and understanding questionnaires and providing written informed consent.
  4. Are willing and able to adhere to the study visit schedule and other protocol-specified procedures.

Exclusion Criteria:

  1. Non-English speaking.
  2. Subjects experiencing an exacerbation of asthma within 6 weeks of Visit 1
  3. Subjects with a forced expiratory volume (FEV1) ≤ 60% predicted, on spirometry
  4. Subjects and medications:

    1. Subjects allergic to methacholine or any other parasympathomimetic agent
    2. Subjects on investigational drugs or participating in interventional research trial(s), 30 days prior to enrollment or during the duration of the study
    3. Subjects currently on β-adrenergic blockers or, a cholinesterase inhibitor
    4. Prior to the administering of the MCT/ EVH test:

    i) use of a short-acting bronchodilator (within 6hrs.) ii) use of a long-acting bronchodilator (within 36hrs.) iii) use of inhaled corticosteroids/ leukotriene modifiers (within 72hrs.) iv) exercise (within 4hrs.)

  5. Subject smoking: in the last 6 months or a smoking history of >10 pack-years
  6. Subjects who have experienced a febrile illness within 3 weeks of Visit 1
  7. Subjects with a history of active poorly controlled epilepsy, cardiovascular disease (esp. with bradycardia), vagotonia, peptic ulcer disease, thyroid disease, or urinary tract obstruction or other chronic ailments that would interfere with the current study
  8. Subjects who are pregnant or refuse medically acceptable contraception during the study period
  9. Subjects with a history of >3 stellate ganglion block procedures
  10. Subjects who have undergone surgical procedures involving the cervical spine
  11. Evidence of coagulopathy with abnormal INR, PT/ PTT and platelet count
  12. Subjects allergic to lidocaine (Subject may still participate in the study if they agree to the procedure without using the Lidoderm patch)
  13. Subjects participating in another interventional research trial
  14. Subjects with a condition or compliance issue, which in the investigator's opinion might interfere with participation in the current study
  15. Subjects unable or unwilling to provide a written consent to undergo the required testing/ procedures/ physical exam or answer the questionnaires

Sites / Locations

  • The Ohio State University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Asthma positive to Methacholine Challenge Testing

Asthma positive to Eucapnic voluntary hyperventilation testing

Arm Description

Asthma diagnosis by positive Methacholine Challenge Testing

Asthma diagnosis by positive Eucapnic voluntary hyperventilation testing

Outcomes

Primary Outcome Measures

Evaluate if neurostimulation of stellate ganglion modulates airway hyperresponsiveness to bronchoprovocation testing. Comparison of FEV1 drop before and after neurostimulation testing will be primary outcome measure
To determine whether neurostimulation of the stellate ganglion modulates airway hyperresponsiveness to bronchoprovocation testing in asthmatics

Secondary Outcome Measures

Evaluate if neurostimulation of the stellate ganglion modulates airway inflammation
To determine whether neurostimulation of the stellate ganglion modulates airway inflammation as measured by exhaled nitric oxide in asthmatics

Full Information

First Posted
October 9, 2012
Last Updated
January 25, 2016
Sponsor
Jonathan Parsons
search

1. Study Identification

Unique Protocol Identification Number
NCT01724307
Brief Title
Stimulation of the Cervical Sympathetic Ganglion for Treatment of Asthma
Official Title
Stimulation of the Cervical Sympathetic Ganglion for Treatment of Asthma.
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
November 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jonathan Parsons

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate if stimulating the nerve involved with airway constriction, while undergoing procedures that are known to cause asthma exacerbations, decreases the level of asthma attack experienced.
Detailed Description
Asthma is a chronic inflammatory disorder of the airways characterized by shortness of breath, wheezing, cough, and fatigue. Some people suffer from sudden worsening of asthma symptoms despite being treated with medications. When people have asthma attacks the muscle tissue in the airway contracts causing the airway to narrow and decreasing the ability for the person to breathe. Neurological pacemakers are FDA approved devices that stimulate nerves in the body and have been used for the treatment of many disorders such as Parkinson's, epilepsy, chronic pain and urinary incontinence. Recent animal studies have shown that stimulating (activating a nerve) the carotid sheath area (located in the neck) can cause the rapid relaxation of the muscles which contract during an asthma attack. This approach has also been successfully used in patients at an emergency room when they came in with a severe asthma attack.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Asthma positive to Methacholine Challenge Testing
Arm Type
Active Comparator
Arm Description
Asthma diagnosis by positive Methacholine Challenge Testing
Arm Title
Asthma positive to Eucapnic voluntary hyperventilation testing
Arm Type
Active Comparator
Arm Description
Asthma diagnosis by positive Eucapnic voluntary hyperventilation testing
Intervention Type
Procedure
Intervention Name(s)
Neurostimulation of stellate ganglion
Intervention Description
An electrical nuerostimulation of the stellate ganglion up to 60 minutes
Primary Outcome Measure Information:
Title
Evaluate if neurostimulation of stellate ganglion modulates airway hyperresponsiveness to bronchoprovocation testing. Comparison of FEV1 drop before and after neurostimulation testing will be primary outcome measure
Description
To determine whether neurostimulation of the stellate ganglion modulates airway hyperresponsiveness to bronchoprovocation testing in asthmatics
Time Frame
60 minutes post treatment
Secondary Outcome Measure Information:
Title
Evaluate if neurostimulation of the stellate ganglion modulates airway inflammation
Description
To determine whether neurostimulation of the stellate ganglion modulates airway inflammation as measured by exhaled nitric oxide in asthmatics
Time Frame
60 minutes post treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients aged 18-70 years of age suffering from mild-to-moderate asthma who have either: bronchial hyper-responsiveness to MCT bronchial hyper-responsiveness to EVH testing All patients with documented evidence of a positive MCT or EVH test within 36 months of Visit 1 Are capable of reading and understanding questionnaires and providing written informed consent. Are willing and able to adhere to the study visit schedule and other protocol-specified procedures. Exclusion Criteria: Non-English speaking. Subjects experiencing an exacerbation of asthma within 6 weeks of Visit 1 Subjects with a forced expiratory volume (FEV1) ≤ 60% predicted, on spirometry Subjects and medications: Subjects allergic to methacholine or any other parasympathomimetic agent Subjects on investigational drugs or participating in interventional research trial(s), 30 days prior to enrollment or during the duration of the study Subjects currently on β-adrenergic blockers or, a cholinesterase inhibitor Prior to the administering of the MCT/ EVH test: i) use of a short-acting bronchodilator (within 6hrs.) ii) use of a long-acting bronchodilator (within 36hrs.) iii) use of inhaled corticosteroids/ leukotriene modifiers (within 72hrs.) iv) exercise (within 4hrs.) Subject smoking: in the last 6 months or a smoking history of >10 pack-years Subjects who have experienced a febrile illness within 3 weeks of Visit 1 Subjects with a history of active poorly controlled epilepsy, cardiovascular disease (esp. with bradycardia), vagotonia, peptic ulcer disease, thyroid disease, or urinary tract obstruction or other chronic ailments that would interfere with the current study Subjects who are pregnant or refuse medically acceptable contraception during the study period Subjects with a history of >3 stellate ganglion block procedures Subjects who have undergone surgical procedures involving the cervical spine Evidence of coagulopathy with abnormal INR, PT/ PTT and platelet count Subjects allergic to lidocaine (Subject may still participate in the study if they agree to the procedure without using the Lidoderm patch) Subjects participating in another interventional research trial Subjects with a condition or compliance issue, which in the investigator's opinion might interfere with participation in the current study Subjects unable or unwilling to provide a written consent to undergo the required testing/ procedures/ physical exam or answer the questionnaires
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathan P Parsons, M.D.
Organizational Affiliation
Ohio State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43221
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Stimulation of the Cervical Sympathetic Ganglion for Treatment of Asthma

We'll reach out to this number within 24 hrs